Merck Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a donation of 100,000 masks.

Citizens and organizations alike are all compelled and inspired to take part in what has become a true global effort, and the biopharmaceutical industry is no exception. As a company dedicated to saving and improving lives, we recognize that we have a special responsibility to help and a duty to contribute to the federal government’s effort in Canada.

“Health care professionals are at the front line of this fight and keeping them safe is critical during a pandemic such as this one”, said AnnA Van Acker, President and General Manager of Merck Canada. “As the need for Personal Protective Equipment (PPE) keeps increasing, we believe we can truly help and have a significant impact in the fight against COVID-19 through this donation”.

Merck Canada also continues to contribute to the COVID-19 fight by remaining focused on protecting the safety of our employees, ensuring that our supply of medicines and vaccines reach our patients and customers, providing support to relief organizations, and supporting patient associations to help them ensure continuance of care of Canadian patients.

We are also extremely proud of the many ways that our employees are helping, either through volunteering services or donations. This includes our medically trained employees who volunteer their time to aid in our healthcare system where needed.

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.